New Horizons in Fetal and Neonatal Alloimmune Thrombocytopenia.
Semin Thromb Hemost
; 49(4): 402-408, 2023 Jun.
Article
en En
| MEDLINE
| ID: mdl-36368687
ABSTRACT
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a common cause of severe thrombocytopenia in newborns. Intracranial bleeding may lead to severe neurological sequelae and mortality. Current management of pregnancies at risk is suboptimal. Prenatal FNAIT diagnosis commonly requires invasive procedures and therapy is associated with a high treatment burden. The present review explores advances in the field and their potential contribution to modification of the diagnostic and therapeutic landscape. Topics addressed include the role of noninvasive prenatal testing using fetal cell free DNA, insights into novel and prospective therapeutic options achieved through the development of murine models of FNAIT as well as the forecast for the progress in pregnancy risk stratification through advancement in the investigation of biological characteristics of alloantibodies and their association with the risk of fetal bleeding.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Antígenos de Plaqueta Humana
/
Trombocitopenia Neonatal Aloinmune
/
Enfermedades Fetales
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
Semin Thromb Hemost
Año:
2023
Tipo del documento:
Article
País de afiliación:
Israel